Agex therapeutics, inc. (AGE)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS ATTRIBUTABLE TO AGEX

-3,187

-2,711

-3,221

-3,089

-3,133

-3,186

-2,151

-1,930

-235

Net loss attributable to noncontrolling interest

-35

-30

-56

-66

-78

-88

-34

-21

-86

Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities:
Gain on sale of equity method investment in Ascendance

-

-

-

-

-

-

-

0

3,215

Acquired in-process research and development

-

-

-

-

-

0

0

0

800

Depreciation expense

123

53

16

12

10

10

23

10

15

Amortization of intangible assets

140

139

140

140

139

140

123

107

107

Amortization of right-of-use asset

104

-

-

-

-

-

-

-

-

Amortization of debt issuance cost

47

-

-

-

-

-

-

-

-

Stock-based compensation

260

420

491

515

481

797

176

167

145

Stock-based compensation allocated from Lineage

-

-

-

-

-

0

34

62

88

Subsidiary stock-based compensation

-

-

-

-

-

0

0

2

2

Income tax provision

-

-

-

-

73

-

-

-

-

Foreign currency remeasurement gain (loss) and other

-5

9

-36

-20

-29

-

-

-

-

Changes in operating assets and liabilities:
Accounts and grants receivable, net

28

129

26

2

75

-60

67

70

-53

Prepaid expenses and other current assets

-195

-142

28

-423

64

119

8

63

29

Accounts payable and accrued liabilities

494

-150

198

173

-52

407

91

-132

282

Related party payables

117

-255

258

-79

8

-16

44

-6

-150

Insurance premium liability

-314

-

-

-

-

-

-

-

-

Deferred revenues and other current liabilities

15

-

-

-

44

-

-

-

-

Deferred revenues

-

-

-

-

-

-

-

-

150

Other current liabilities

-

-

-

-

-

-

-

-

68

Net cash used in operating activities

-2,064

-2,411

-2,649

-2,482

-2,618

-2,046

-1,783

-2,161

-2,005

CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of equity method investment in Ascendance

-

-

-

-

-

0

0

0

3,215

Purchase of in-process research and development

-

-

-

-

-

0

1,072

0

800

Purchase of equipment and other

4

295

237

106

3

0

8

12

1

Net cash used in investing activities

-4

-295

120

-183

-3

3

-1,078

-12

2,414

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of warrants

-

-

-

-

-

0

263

0

737

Proceeds from exercise of warrants

-

0

0

0

4,500

-

-

-

-

Draw down on loan facility from Juvenescence

200

-

-

-

-

-

-

-

-

Repayment of financing lease liability

15

-

-

-

-

-

-

-

-

Net cash provided by financing activities

185

1,287

487

-9

4,500

0

263

5,000

737

Effect of exchange rate changes on cash and cash equivalents

-1

-

-

-

-

-

-

-

-

NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-1,884

-

-

-

1,879

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

8

-1

CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
NET INCREASE IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

-

-

1,145